Research ArticleOriginal Article
Open Access

Renin-angiotensin-system blockers and IgG antibodies in end-stage renal disease hemodialysis-receiving patients diagnosed with COVID-19 infection

Sultan A. Almdallaleh, Abdulkareem O. Alsuwaida, Abdulhadi M. Altalhi, Dina M. ALJayar, Elzibair E. Massad, Mazaher M. Hamid, Parameaswari P. Jaganathan and Fadel H. Al-Hababi
Saudi Medical Journal September 2023, 44 (9) 875-881; DOI: https://doi.org/10.15537/smj.2023.44.9.20230129

References

  1. 1.↵
    1. Cho JH,
    2. Kang SH,
    3. Park HC,
    4. Kim DK,
    5. Lee SH,
    6. Do JY, et al.
    Hemodialysis with cohort isolation to prevent secondary transmission during a COVID-19 outbreak in Korea. J Am Soc Nephrol 2020; 31: 1398–1408.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    National Center for Immunization and Respiratory Diseases (US). Interim additional guidance for infection prevention and control recommendations for patients with suspected or confirmed COVID-19 in outpatient hemodialysis facilities. [Updated 2020; accessed 2023 Jul 10]. Available from: https://stacks.cdc.gov/view/cdc/85730
  3. 3.↵
    1. Corbett RW,
    2. Blakey S,
    3. Nitsch D,
    4. Loucaidou M,
    5. McLean A,
    6. Duncan N, et al.
    Epidemiology of COVID-19 in an urban dialysis center. J Am Soc Nephrol 2020; 31: 1815–1823.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Post N,
    2. Eddy D,
    3. Huntley C,
    4. van Schalkwyk MCI,
    5. Shrotri M,
    6. Leeman D, et al.
    Antibody response to SARS-CoV-2 infection in humans: a systematic review. PLoS One 2020; 15: e0244126.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Xiang F,
    2. Wang X,
    3. He X,
    4. Peng Z,
    5. Yang B,
    6. Zhang J, et al.
    Antibody detection and dynamic characteristics in patients with coronavirus disease-19. Clin Infect Dis 2020; 71: 1930–1934.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Ma H,
    2. Zeng W,
    3. He H,
    4. Zhao D,
    5. Jiang D,
    6. Zhou P, et al.
    Serum IgA, IgM, and IgG responses in COVID-19. Cell Mol Immunol 2020; 17: 773–775.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Zost SJ,
    2. Gilchuk P,
    3. Case JB,
    4. Binshtein E,
    5. Chen RE,
    6. Reidy JX, et al.
    Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals. [Updated 2020; 2020 May 22]. Available from: https://www.biorxiv.org/content/10.1101/2020.05.22.111005v1
  8. 8.↵
    1. Rogers TF,
    2. Zhao F,
    3. Huang D,
    4. Beutler N,
    5. Burns A,
    6. He WT, et al.
    Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science 2020; 369: 956–963.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Zhao J,
    2. Yuan Q,
    3. Wang H,
    4. Liu W,
    5. Liao X,
    6. Su Y, et al.
    Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease-19. Clin Infect Dis 2020; 71: 2027–2034
    OpenUrlCrossRefPubMed
  10. 10.↵
    Public Health Authority. Coronavirus disease: COVID-19 guidlines (V 3.1). [Updated 2023; 2021 Oct 15]. Available from: https://covid19.cdc.gov.sa/wp-content/uploads/2023/04/V3.1COVID-19-Coronavirus-Disease-Guidelinesfinal-editionApr4-en.pdf
  11. 11.↵
    1. Arons MM,
    2. Hatfield KM,
    3. Reddy SC,
    4. Kimball A,
    5. James A,
    6. Jacobs JR, et al.
    Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med 2020; 382: 2081–2090.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Ai T,
    2. Yang Z,
    3. Hou H,
    4. Zhan C,
    5. Chen C,
    6. Lv W, et al.
    Correlation of chest CT and RT-PCR testing for coronavirus disease-19 (COVID-19) in China: a report of 1014 cases. Radiology 2020; 296: E32–E40.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Clarke C,
    2. Prendecki M,
    3. Dhutia A,
    4. Ali MA,
    5. Sajjad H,
    6. Shivakumar O, et al.
    High prevalence of asymptomatic COVID-19 infection in hemodialysis patients detected using serologic screening. J Am Soc Nephrol 2020; 31: 1969–1975.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Housawi AA,
    2. Qazi SJS,
    3. Jan AA,
    4. Osman RA,
    5. Alshamrani MM,
    6. AlFaadhel TA, et al.
    Prevalence of anti-SARS-CoV-2 antibody in hemodialysis facilities: a cross-sectional multicenter study from Madinah. Ann Saudi Med 2022; 42: 246–251.
    OpenUrl
  15. 15.↵
    National Kidney Foundation. KDOQI clinical practice guideline for hemodialysis adequacy: 2015 update. Am J Kidney Dis 2015; 66: 884–930.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Chen CY,
    2. Liu KT,
    3. Shih SR,
    4. Ye JJ,
    5. Chen YT,
    6. Hsu CK, et al.
    Adequacy of hemodialysis serves as an independent predictor of humoral response to ChAdOx1 prime-boost vaccination in hemodialysis patients. Viruses 2022; 14: 1149.
    OpenUrl
  17. 17.↵
    1. Tung KT,
    2. Peng YS,
    3. Hsu SP,
    4. Wu HY,
    5. Chiu YL,
    6. Yang JY, et al.
    Humoral antibody response to the first dose of the ChAdOx1 nCoV-19 vaccine in Asian patients undergoing hemodialysis. Hemodial Int 2022; 26: 369–376.
    OpenUrl
  18. 18.↵
    1. Letko M,
    2. Marzi A,
    3. Munster V.
    Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol 2020; 5: 562–569.
    OpenUrl
  19. 19.↵
    1. Fang L,
    2. Karakiulakis G,
    3. Roth M.
    Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020; 8: e21.
    OpenUrl
  20. 20.↵
    1. Sommerstein R,
    2. Kochen MM,
    3. Messerli FH,
    4. Gräni C.
    Coronavirus disease 2019 (COVID-19): do angiotensin-converting enzyme inhibitors/angiotensin receptor blockers have a biphasic effect? J Am Heart Assoc 2020; 9: e016509.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Zhang P,
    2. Zhu L,
    3. Cai J,
    4. Lei F,
    5. Qin JJ,
    6. Xie J, et al.
    Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res 2020; 126: 1671–1681.
    OpenUrlPubMed
  22. 22.↵
    1. Gao C,
    2. Cai Y,
    3. Zhang K,
    4. Zhou L,
    5. Zhang Y,
    6. Zhang X, et al.
    Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J 2020; 41: 2058–2066.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Feng B,
    2. Zhang D,
    3. Wang Q,
    4. Yu F,
    5. Zou Q,
    6. Xie G, et al.
    Effects of angiotensin II receptor blocker usage on viral load, antibody dynamics, and transcriptional characteristics among COVID-19 patients with hypertension. Journal of Zhejiang University-SCIENCE B 2021; 22: 330–340.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords